Real-time funding, M&A, exec moves & hiring — the signals that move deals
More real-time opportunities that match your ICP — every funding, M&A, and exec move the moment it breaks, with the verified contacts to reach out first.
Funding, M&A, exec moves & hiring — every signal Fundz sees, the moment it happens. See who’s in your market, who to reach, and why now.
Eton Pharmaceuticals acquires HEMANGEOL rights
PUBLIC · ETONMar 19, 2026•4 months ago
Acquiring Company
Eton Pharmaceuticals
Acquired Company
Hemangeol
Deer ParkBiotechnologyHealthcareHealth CarePharmaceuticalBiotechnologyHealth Care
Description
Eton Pharmaceuticals has acquired U.S. rights to the orphan drug HEMANGEOL, expected to enhance their sales strategy in pediatric dermatology. This acquisition is aligned with Eton's growth initiatives and will allow them to integrate HEMANGEOL into their existing patient support programs. The commercialization of HEMANGEOL is scheduled for May 1st, further boosting Eton's portfolio of rare disease treatments.
Company Information
Company
Eton Pharmaceuticals
Location
Deer Park, Illinois, United States
About
Eton Pharmaceuticals is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases.
Deer ParkBiotechnologyHealthcareHealth CarePharmaceuticalBiotechnologyHealth Care